Loading...
•
Sep 30, 2021
Personalis Q3 2021 Earnings Report
Personalis reported a revenue increase of 12% compared to the same quarter last year, driven by a 50% growth in revenue from oncology customers.
Key Takeaways
Personalis, Inc. reported financial results for the third quarter ended September 30, 2021, with a revenue of $22.3 million, a 12% increase compared to the third quarter of 2020. The company's revenue from oncology customers grew 50% over the same period last year. Personalis is preparing to launch NeXT Personal, its Minimal Residual Disease (MRD) offering in December.
Reported quarterly revenue of $22.3 million, a 12% increase year-over-year.
Revenue from biopharma and all other customers, excluding the VA MVP, reached a record $8.6 million, a 50% increase year-over-year.
Received a new order from the VA MVP with an aggregate value of approximately $10 million over a six-month period.
Announced a collaboration with Mayo Clinic to provide clinical-grade comprehensive cancer genomic sequencing for patients.
Forward Guidance
Personalis expects total revenue to be in the range of $20.2 million to $20.4 million and net loss to be in the range of $22 million to $23 million for the fourth quarter of 2021. For the full year of 2021, Personalis expects total revenue to be approximately $85 million and net loss to be in the range of $67 million to $68 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...